BioCentury
ARTICLE | Clinical News

RE-024: Phase I data

March 28, 2016 7:00 AM UTC

A double-blind, placebo-controlled Phase I trial in 40 healthy volunteers showed that single doses of 75, 225, 450, 900 and 1,800 mg oral RE-024 were well tolerated with no serious adverse events repo...